six The phosphodiesterase-5 inhibitor sildenafil is certified for PAH in FC I–IV in the United states of america and FC II–III in Europe. Endothelin receptor antagonists (ERAs) including bosentan, sitaxentan and ambrisentan are oral therapies certified for use in PAH. As no oral agent has demonstrated superiority there stays debate concerning w